10-K: Precision Optics Reports Wider Losses, Margin Decline in FY25

Precision Optics Corporation, Inc. reported a significant increase in net loss and a sharp decline in gross margin for the fiscal year ended June 30, 2025, despite flat revenues and successful capital raises.

Summary

• Total revenues for the fiscal year ended June 30, 2025, were $19,091,269, a slight decrease of 0.1% from $19,104,350 in the prior year.
• Gross profit decreased to $3,404,433 (17.8% margin) in FY2025 from $5,797,777 (30.3% margin) in FY2024, primarily due to yield issues with new manufacturing lines and lower utilization of billable engineering resources.
• Net loss significantly widened to $(5,780,246) in FY2025, compared to $(2,951,377) in FY2024.
• Loss per share (basic and fully diluted) was $(0.85) in FY2025, worsening from $(0.49) in FY2024.
• Net cash used in operating activities increased to $(3,547,400) in FY2025 from $(2,683,012) in FY2024.
• The company successfully raised approximately $1.2 million net in August 2024 and $5.1 million gross in February 2025 through registered direct offerings.
• Systems Manufacturing revenue increased by 122.2% to $8,290,225 in FY2025, driven by the transfer of design services engagements to production.
• Engineering Design Services revenue decreased by 42.0% to $4,938,158 in FY2025, attributed to program transfers to production, increased internal R&D, and delayed revenue opportunities.
• The Unity Imaging Platform, a standard baseline CMOS endoscopic system, was launched in January 2025, aiming to accelerate customer time to market.
• The company did not meet its minimum annual debt service coverage ratio covenant for both FY2024 and FY2025 but received waivers from Main Street Bank, with the FY2025 waiver contingent on a $30,000 fee and a $4.5 million equity raise, which was satisfied.

Sentiment

Score: 3

Explanation: The company's financial performance deteriorated significantly with a widening net loss, substantial gross margin decline, and increased cash burn from operations. While capital raises provided liquidity and the Unity Platform launched, ongoing debt covenant issues and reliance on external financing for operational needs indicate significant underlying challenges and a high-risk profile.

Positives

• Systems Manufacturing revenue increased significantly by 122.2% to $8,290,225 in FY2025, indicating successful transition of design projects to production.
• Launched the Unity Imaging Platform in January 2025, a modular and adaptable endoscopic system designed to shorten time to market for customers.
• Successfully completed two registered direct offerings in August 2024 and February 2025, raising approximately $1.2 million net and $5.1 million gross, respectively, improving liquidity.
• Management concluded that internal control over financial reporting and disclosure controls and procedures were effective as of June 30, 2025.
• Maintained strong relationships with employees, with no collective bargaining agreements and good employee relations reported.

Negatives

• Net loss widened substantially to $(5,780,246) in FY2025 from $(2,951,377) in FY2024.
• Gross margin decreased significantly to 17.8% in FY2025 from 30.3% in FY2024, primarily due to yield issues with new manufacturing lines and lower utilization of billable engineering resources.
• Net cash used in operating activities increased to $(3,547,400) in FY2025, indicating a higher cash burn rate.
• Engineering Design Services revenue decreased by 42.0% in FY2025, partly due to unplanned increases in non-billable sustaining engineering activity and delayed revenue opportunities.
• MicroOptics Lab revenue decreased by 21.5% and Ross Optical Industries revenue decreased by 9.8% in FY2025, with Ross Optical's decline attributed to an industry-wide slowdown and tariff uncertainty.
• The company failed to meet its minimum annual debt service coverage ratio covenant for both FY2024 and FY2025, requiring waivers from its lender.
• Future advances on the revolving line of credit are contingent on achieving a minimum Debt Service Coverage ratio of 1.20x, which the company was not in compliance with as of June 30, 2025.
• Two customers accounted for approximately 22% and 20% of total revenues in FY2025, posing a significant customer concentration risk.

Risks

• History of losses and potential for continued losses, requiring additional capital raises.
• Reliance on a small number of customers, with the loss of any potentially having a material adverse effect on revenues.
• Risk of unrecoverable losses on accounts receivable.
• Heavy dependence on the Chief Executive Officer and other senior officers; loss of key personnel could damage the business.
• Inability to attract and retain employees with necessary scientific and technical skills.
• High degree of regulatory oversight (FDA, ITAR); failure to obtain or maintain necessary approvals could harm the business.
• Risks inherent in product development and production under fixed-price purchase orders, which may not be profitable over time.
• Customers may decide to use other vendors for engineering and manufacturing services.
• Ross Optical's reliance on third-party sourced products, leading to potential customer switching or price pressure.
• Dependence on a few sources for key supplies (precision-grade optical glass, CMOS sensors) and services.
• Exposure to product liability claims, with insurance potentially insufficient to cover all future claims.
• Potential for severe damage to business from failure to comply with environmental laws.
• Competition from larger, well-financed companies with superior resources.
• Ross Optical is subject to tariffs and regulatory scrutiny, with changes potentially affecting international supply chain, costs, and competitive position.
• Cyber-attacks on information technology infrastructure and products, leading to potential disruptions, data breaches, and financial losses.
• Third parties may infringe on intellectual property, leading to significant protection expenses or inability to defend patents.
• Claims of infringement on third-party patents, potentially leading to costly litigation or prohibition from using certain technologies.
• Claims that employees have wrongfully used or disclosed trade secrets of former employers.
• Inability to adequately prevent disclosure of trade secrets and other proprietary information.
• Inability to protect intellectual property rights globally due to prohibitive costs and varying legal protections.
• Substantial volatility in common stock trading price due to various factors.
• Quarterly financial results may vary significantly, making predictions difficult.
• Future issuance of additional capital stock could dilute existing stockholders' percentage interest.
• Failure to maintain effective internal control over financial reporting could lead to inaccurate financial statements.
• Certain provisions in organizational documents could enable the board of directors to prevent or delay a change of control.
• Negative research about the business published by analysts or journalists could cause stock price to decline.
• Claims for indemnification by directors and officers may reduce available funds.
• No intention of declaring dividends in the foreseeable future, making investors dependent on stock appreciation.
• Artificial intelligence presents risks and challenges, including security risks to confidential information and potential liability.

Future Outlook

Management generally expects revenue to increase over time as the engineering design phase of new product programs is completed and products transition to the commercial phase, leveraging unique manufacturing capabilities. The company intends to continue aggressively supporting and augmenting internal engineering, research and development resources and pursuing patent protection for existing and new technology. Future advances on the revolving line of credit are contingent on achieving a minimum Debt Service Coverage ratio of 1.20x based on quarterly testing, which was not met as of June 30, 2025. The company does not anticipate declaring any dividends in the foreseeable future, intending to use any excess cash to fund operations.

Management Comments

• We generally expect revenue to increase over time as the engineering design phase of new product programs is completed and products transition to the commercial phase, leveraging our unique manufacturing capabilities.
• We believe our Microprecision optics technology provides a solution to the challenge of combining smaller endoscope sizes with acceptable image quality at reasonable manufacturing costs.
• We believe the technology developed to support the design, fabrication and manufacturing of Microprecision lenses and associated assemblies can also be used to satisfy the needs of defense and aerospace systems that require small size and weight, particularly those required for satellite network communications.
• We believe that our unique technical capabilities in the areas of Microprecision optics, micro medical cameras, digital imaging, and illumination represent competitive advantages for us in the minimally invasive surgical device market.
• We believe that our future success depends, to a large degree, on our ability to continue to conceive and develop new optical products and technologies to enhance the performance characteristics and methods of manufacture of existing and new products.
• Based on our current plans and business conditions, management believes that the Company's available cash and cash equivalents, the cash generated from operations, availability on our line of credit, and our ability to raise funds in the capital markets will be sufficient to provide for the Company's working capital and capital expenditure requirements for at least 12 months from the date of this filing.

Industry Context

The company operates in highly competitive markets for medical devices and advanced defense/aerospace products, facing larger competitors with greater resources. The medical device industry continues to demand smaller, disposable, and enhanced imaging systems for minimally invasive surgery, a trend Precision Optics aims to capitalize on with its Microprecision optics and digital imaging technologies, including the new Unity Platform. The defense/aerospace sector also seeks smaller, lighter systems, particularly for satellite network communications, aligning with the company's technological applications. The Ross Optical division faces industry-wide slowdowns and uncertainties from evolving tariff costs, reflecting broader global trade challenges impacting supply chains.

Comparison to Industry Standards

• The significant decline in gross margin to 17.8% is notably below typical benchmarks for specialized manufacturing and high-tech medical device components, where margins often range from 30% to 60% or higher, depending on proprietary technology and market position. This suggests operational inefficiencies or pricing pressures not fully offset by value-added services.
• The increased net loss and cash burn from operations indicate a challenging financial performance compared to industry peers that are typically profitable or demonstrating a clear path to profitability in mature product segments.
• The reliance on debt covenant waivers and frequent equity raises for working capital suggests a weaker financial position and higher risk profile compared to more financially stable industry players who can fund growth through internal cash generation or less dilutive financing.
• The launch of the Unity Platform, a modular endoscopic system, aligns with industry trends towards integrated, customizable, and efficient solutions for medical imaging, similar to offerings from larger medical technology companies like Stryker or Karl Storz, though Precision Optics focuses on micro-precision and OEM solutions.

Corporate Governance

Legal Proceedings

• Not currently aware of any pending or threatened litigation against the company or its officers and directors that could have a material impact on operations or finances.

Related Party Transactions

• The company leases its primary facility in Gardner, Massachusetts, from Equity Assets, Inc. (EAI). EAI shares were distributed to five beneficiaries, including CEO Joseph N. Forkey, who now holds a 20% interest. Dr. Forkey is president of EAI but is recused from negotiations with the company.
• Dr. Forkey's 20% interest in rents received from the company through EAI amounts to $21,600 per year.
• Certain directors and officers of the company participated in the registered direct offering in August 2024, purchasing shares at $5.79 per share.

Stakeholder Impact

• **Shareholders**: Face significant dilution from recent and potential future equity raises. The increased net loss and decreased gross margin negatively impact shareholder value and earnings per share. Stock price volatility is a noted risk, and no dividends are expected, making returns dependent on stock appreciation.
• **Employees**: The company had 90 full-time employees as of June 30, 2025, with good relations reported. Stock-based compensation is a component of overall compensation, potentially aligning employee incentives with company performance.
• **Customers**: Benefit from the company's focus on advanced optical instruments, custom designs, and new technologies like the Unity Platform. However, the risk of customers switching vendors or postponing deliveries (e.g., Ross Optical) could impact future business relationships.
• **Suppliers**: The company's dependence on a few key suppliers for critical components (precision-grade optical glass, CMOS sensors) creates a concentration risk for its supply chain, potentially affecting product delivery and costs.
• **Creditors (Main Street Bank)**: The company's failure to meet debt service coverage ratio covenants and reliance on waivers indicates increased credit risk. While waivers were granted, future advances are contingent on meeting financial ratios not currently in compliance, posing ongoing challenges for debt management.

Next Steps

• Continue to aggressively support and augment internal engineering, research and development resources.
• Pursue patent protection for existing and new technology, particularly for micro medical cameras.
• Expand the pipeline of projects for established and emerging medical device companies, as well as defense/aerospace companies.
• Commence payments of principal and interest under the Term Loan and Promissory Note beginning April 15, 2025, following a six-month interest-only period.
• Work towards achieving a minimum Debt Service Coverage ratio of 1.20x for future advances on the revolving line of credit, as compliance was not met as of June 30, 2025.
• Evaluate the impact of new accounting standards (ASU 2023-09 and ASU 2024-03/2025-01) on future financial disclosures.
• Operate new leased facilities in South Portland, Maine (commenced August 1, 2025) and Littleton, Massachusetts (commenced September 10, 2025).

Key Dates

Recommendation

The company's financial performance for FY2025 shows significant deterioration, with a substantially widened net loss and a sharp decline in gross margin. Cash burn from operations increased, and the company's inability to meet debt covenants, requiring waivers, highlights underlying financial instability. While capital raises provided short-term liquidity and new product initiatives like the Unity Platform offer future potential, the current operational challenges, high customer concentration, and reliance on external financing for basic operations suggest a high-risk investment with a negative outlook for profitability in the near term. A seasoned investor would likely view these results as a strong indicator to divest or avoid the stock.

Keywords

Optical Instruments, Medical Devices, Defense/Aerospace, Endoscopes, Micro-optics, CMOS Sensors, Systems Manufacturing, Engineering Design, Ross Optical, Unity Platform, SEC Filing, 10-K, Financial Reporting